- Ocrelizumab approved in US for relapsing and progressive MS
- Kidney and bladder stone risk
- ADHD in children of women with MS
Ocrelizumab (Ocrevus) has become the first medicine to be licensed for primary progressive MS by the FDA (Food and Drug Administration), the American drug regulators. The FDA has also licensed ocrelizumab as a treatment for relapsing remitting MS.
- Anxiety and the link to depression
- Anxiety and psychosocial factors
- Invisible disability toilet signs
- Trigeminal neuralgia at onset of MS
Sign up to our Northamptonshire Big Blue Jump before Wednesday 5 April and sign up a friend for FREE!
- Early treatment with disease modifying drugs
- Contraceptives and relapses
- Neurological services declining
- Access to neurologists
- Myelin repair research
- Caroline Wyatt and stem cell therapy
- Daclizumab (Zinbryta) approved in England and Wales
- Delayed acceptance of NICE approved drugs
- Prescription charge rises
NICE (National Institute for Health and Care Excellence) has approved Zinbryta (daclizumab) as a treatment for relapsing remitting multiple sclerosis on the NHS in England and Wales.
Two new reports published this week have highlighted the problems facing people trying to access neurological services in the UK
Researchers have discovered a protein that encourages the regrowth of myelin and may lead to new types of treatment for MS in the future
- Surgery to open up narrowed veins not effective in MS
- Kadeena Cox on MS
- Runner with MS sets herself 1000km challenge
Canadian researchers have presented preliminary results from a clinical study which suggest that surgical treatment to unblock veins draining the brain and spinal cord is not effective in treating MS.